Evidence map›Paper›PMID 34739044›Full record

ArticleThe Journal of infectious diseases2021

IL-4i1 Regulation of Immune Protection During Mycobacterium tuberculosis Infection.

Lerato Hlaka, Mumin Ozturk, Julius E Chia, Shelby-Sara Jones, Shandre Pillay, Sibongiseni K L Poswayo, Thabo Mpotje, Justin K Nono, Simphiwe R N Simelane, Suraj P Parihar and 4 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 4 countries.

Lerato HlakaInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Mumin OzturkInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Julius E ChiaInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Shelby-Sara JonesInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Shandre PillayInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Sibongiseni K L PoswayoInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Thabo MpotjeInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Justin K NonoInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Simphiwe R N SimelaneInstitute of Infectious Diseases and Molecular Medicine (IDM), Division of Immunology and South African Medical Research Council (SAMRC) Immunology of Infectious Diseases, Department of Pathology, Faculty of Health Sciences, University of Cape Town, Cape Town 7925, South Africa.
Suraj P PariharInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Sugata RoyRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Harukazu SuzukiRIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Frank BrombacherInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
Reto GulerInternational Centre for Genetic Engineering and Biotechnology, Cape Town Component, Cape Town, South Africa.
International Centre for Genetic Engineering and Biotechnology · ZASouth African Medical Research Council · ZAUniversity of Cape Town · ZARIKEN Center for Integrative Medical Sciences · JP

Funding

Medical Research Council MR/P028071/1Wellcome TrustWellcome Trust 203135Z/16/Z
6 · The paper itself

Abstract

backgroundInterleukin 4 (IL-4i1)-induced gene 1 encodes L-phenylalanine oxidase that catabolizes phenylalanine into phenylpyruvate. IL-4i1 is mainly expressed by antigen-presenting cells (APCs), inhibits T-cell proliferation, regulates B-cell activation, modulates T cell responses, and drives macrophage polarization, but its role in bacterial infections is understudied.

methodsWe evaluated IL-4i1 deletion in macrophages and mice on infection with virulent H37Rv and W-Beijing lineage hypervirulent HN878 Mycobacterium tuberculosis (Mtb) strains. The bacterial growth and proinflammatory responses were measured in vitro and in vivo. Histopathological analysis, lung immune cell recruitment, and macrophage activation were assessed at the early and chronic stages of Mtb infection.

resultsIL-4i1-deficient (IL-4i1-/-) mice displayed increased protection against acute H37Rv, HN878 and chronic HN878 Mt infections, with reduced lung bacterial burdens and altered APC responses compared with wild-type mice. Moreover, "M1-like" interstitial macrophage numbers, and nitrite and Interferon-γ production were significantly increased in IL-4i1-/- mice compared with wild-type mice during acute Mtb HN878 infection.

conclusionsTogether, these data suggest that IL-4i1 regulates APC-mediated inflammatory responses during acute and chronic Mtb infection. Hence, IL-4i1 targeting has potential as an immunomodulatory target for host-directed therapy.

Indexed as

ImmunityTuberculosisAnimalsMacrophage ActivationMacrophagesMiceMycobacterium tuberculosisT-Lymphocyteshost-directed therapyIL-4i1immunityMycobacterium tuberculosis

Identifiers

PMID34739044
PMCPMC8672763
OpenAlexW3208667845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.